MDGL
Madrigal Pharmaceuticals, Inc.
$510.04
-4.64%
2026-05-08
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Key Fundamentals
Forward P/E
41.34
EPS (TTM)
$-13.48
ROE
-49.3%
Revenue Growth (YoY)
126.8%
Profit Margin
-27.3%
Debt/Equity
63.60
Price/Book
19.82
Beta
-1.04
Market Cap
$12.06B
Avg Volume (10D)
269K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$572.20
60D Low
$416.21
Avg Volume
330K
Latest Close
$510.04
Get breakout alerts for MDGL
Sign up for Breakout Scanner to receive daily notifications when MDGL triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Madrigal Pharmaceuticals, Inc. (MDGL) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors MDGL daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. MDGL operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.